Source: Teva nears deal for Allergan's generic drugs unit
Teva Pharmaceutical Industries Ltd. is in advanced talks to buy Allergan Plc's generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter.
Jerusalem-based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin-based Allergan's generic drugs unit for between $40 billion and $45 billion, the person said on Saturday. A deal could be announced as early as next week, the person said, cautioning that negotiations had not yet been completed and asking not to be identified because the discussions are confidential. Teva and Allergan representatives did not respond to requests for comment.
